Wockhardt moves closer to Europe launch, files EMA application for WCK 5222Wockhardt moves closer to Europe launch, files EMA application for WCK 5222

Introduction

Leading pharmaceutical firm filed a Marketing Authorisation Application with EMA for WCK 5222, a novel antibiotic targeting resistant Gram-negative infections, eligible for accelerated assessment across 30 European countries.

Also Read: SKM Egg Products rises 5% after company reports no bird flu impact on Tamil Nadu operations

Share price movement of Wockhardt

On January 7, 2026, Wockhardt Ltd opened at ₹1,465.00, up 0.35% from its previous close of ₹1,464.90. The stock reached a high of ₹1,481.55 (1.17%) and a low of ₹1,461.15. By 11:19 AM, it traded at ₹1,470.10, a 0.35% increase, with a market cap of ₹23,887.00 crore.

Wockhardt Files EMA Application for WCK 5222

Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222 on January 5, 2026, covering 30 European countries.

WCK 5222 is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g). The EMA has granted it Accelerated Assessment due to its potential to address unmet medical needs.

The drug is also under fast-track review by the US FDA. Wockhardt expects approval for resistant Gram-negative infections, making it the first Indian-discovered New Chemical Entity submitted for pan-European authorisation.

Stock performance of Wockhardt for Period of 1 week, 6 months, and 1 year

Wockhardt Ltd delivered a 1.35% return over the past week, declined by 16.6% in the past six months, and fell 1.19% over the past year.

Also Read: ONGC forms joint ventures with Japan’s MOL to enter ethane shipping business

Shareholding pattern of Wockhardt

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	49.10%	49.10%	49.10%
FII	7.10%	7.30%	6.80%
DII	11.00%	11.00%	10.60%
Public	33%	33%	33.50%

About Wockhardt

Wockhardt Ltd (NSE: WOCKPHARMA) focuses on antibiotic innovation, developing treatments for multi-drug resistant infections, with six antibiotics in its pipeline, three approved, and two in final clinical development stages.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs